Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Bartter's and Gitelman's syndrome.

Seyberth HW, Weber S, Kömhoff M.

Curr Opin Pediatr. 2017 Apr;29(2):179-186. doi: 10.1097/MOP.0000000000000447. Review.

PMID:
27906863
2.

Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations.

Laghmani K, Beck BB, Yang SS, Seaayfan E, Wenzel A, Reusch B, Vitzthum H, Priem D, Demaretz S, Bergmann K, Duin LK, Göbel H, Mache C, Thiele H, Bartram MP, Dombret C, Altmüller J, Nürnberg P, Benzing T, Levtchenko E, Seyberth HW, Klaus G, Yigit G, Lin SH, Timmer A, de Koning TJ, Scherjon SA, Schlingmann KP, Bertrand MJ, Rinschen MM, de Backer O, Konrad M, Kömhoff M.

N Engl J Med. 2016 May 12;374(19):1853-63. doi: 10.1056/NEJMoa1507629. Epub 2016 Apr 27.

3.

Pathophysiology and clinical presentations of salt-losing tubulopathies.

Seyberth HW.

Pediatr Nephrol. 2016 Mar;31(3):407-18. doi: 10.1007/s00467-015-3143-1. Epub 2015 Jul 16. Review.

PMID:
26178649
4.

Historical development of pediatric pharmacology.

Seyberth HW, Rane A, Schwab M.

Handb Exp Pharmacol. 2011;205:v-vi. No abstract available.

PMID:
22046631
5.

Basics and dynamics of neonatal and pediatric pharmacology.

Seyberth HW, Kauffman RE.

Handb Exp Pharmacol. 2011;205:3-49. doi: 10.1007/978-3-642-20195-0_1.

PMID:
21882104
6.

Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects.

Seyberth HW, Schlingmann KP.

Pediatr Nephrol. 2011 Oct;26(10):1789-802. doi: 10.1007/s00467-011-1871-4. Epub 2011 Apr 19. Review.

7.

Loop disorders: insights derived from defined genotypes.

Jeck N, Seyberth HW.

Nephron Physiol. 2011;118(1):p7-14. doi: 10.1159/000320882. Epub 2010 Nov 11.

PMID:
21071987
8.

Problems of prescription drug use in children.

Seyberth HW.

Dtsch Arztebl Int. 2009 Jan;106(3):23-4. doi: 10.3238/arztebl.2009.0023. Epub 2009 Jan 16. No abstract available.

9.

An improved terminology and classification of Bartter-like syndromes.

Seyberth HW.

Nat Clin Pract Nephrol. 2008 Oct;4(10):560-7. doi: 10.1038/ncpneph0912. Epub 2008 Aug 12. Review.

PMID:
18695706
10.

Hereditary Hypokalemic Salt-losing Tubular Disorders.

Peters M, Konrad M, Seyberth HW.

Saudi J Kidney Dis Transpl. 2003 Jul-Sep;14(3):386-97.

11.

Late-onset manifestation of antenatal Bartter syndrome as a result of residual function of the mutated renal Na+-K+-2Cl- co-transporter.

Pressler CA, Heinzinger J, Jeck N, Waldegger P, Pechmann U, Reinalter S, Konrad M, Beetz R, Seyberth HW, Waldegger S.

J Am Soc Nephrol. 2006 Aug;17(8):2136-42. Epub 2006 Jun 28.

12.

Effective NSAID treatment indicates that hyperprostaglandinism is affecting the clinical severity of childhood hypophosphatasia.

Girschick HJ, Schneider P, Haubitz I, Hiort O, Collmann H, Beer M, Shin YS, Seyberth HW.

Orphanet J Rare Dis. 2006 Jun 28;1:24.

13.

Renal cortical regulation of COX-1 and functionally related products in early renovascular hypertension (rat).

Theilig F, Debiec H, Nafz B, Ronco P, Nüsing R, Seyberth HW, Pavenstädt H, Bouby N, Bachmann S.

Am J Physiol Renal Physiol. 2006 Nov;291(5):F987-94. Epub 2006 Jun 20.

14.

Increased systolic blood pressure with rofecoxib in congenital furosemide-like salt loss.

Kömhoff M, Klaus G, Nazarowa S, Reinalter SC, Seyberth HW.

Nephrol Dial Transplant. 2006 Jul;21(7):1833-7. Epub 2006 Mar 22.

PMID:
16554326
15.

Perinatal management of a preterm neonate affected by hyperprostaglandin E2 syndrome (HPS).

Kömhoff M, Tekesin I, Peters M, Leonhard A, Seyberth HW.

Acta Paediatr. 2005 Nov;94(11):1690-3.

PMID:
16303714
16.

Developing a European framework for research on children's medicines: an examination of the proposed EU regulation on medicinal products for paediatric use.

Seyberth HW, Demotes-Mainard J, Wrobel P.

Pediatr Nephrol. 2005 Nov;20(11):1537-40. Epub 2005 Sep 16. No abstract available.

PMID:
16167134
17.

Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia.

Schlingmann KP, Sassen MC, Weber S, Pechmann U, Kusch K, Pelken L, Lotan D, Syrrou M, Prebble JJ, Cole DE, Metzger DL, Rahman S, Tajima T, Shu SG, Waldegger S, Seyberth HW, Konrad M.

J Am Soc Nephrol. 2005 Oct;16(10):3061-9. Epub 2005 Aug 17.

18.

Pharmacokinetics of a novel oral slow-release form of misoprostol.

Fiala C, Aronsson A, Granath F, Stephansson O, Seyberth HW, Watzer B, Gemzell-Danielsson K.

Hum Reprod. 2005 Dec;20(12):3414-8. Epub 2005 Jul 29.

PMID:
16055461
19.

[Drug therapy in childhood and adolescence. A challenge between patient protection and therapy safety].

Brochhausen C, Seyberth HW.

Kinderkrankenschwester. 2003 Jan;22(1):8-11. German. No abstract available.

PMID:
15984430
20.

Dominant role of prostaglandin E2 EP4 receptor in furosemide-induced salt-losing tubulopathy: a model for hyperprostaglandin E syndrome/antenatal Bartter syndrome.

Nüsing RM, Treude A, Weissenberger C, Jensen B, Bek M, Wagner C, Narumiya S, Seyberth HW.

J Am Soc Nephrol. 2005 Aug;16(8):2354-62. Epub 2005 Jun 23.

21.

Functional evaluation of Dent's disease-causing mutations: implications for ClC-5 channel trafficking and internalization.

Ludwig M, Doroszewicz J, Seyberth HW, Bökenkamp A, Balluch B, Nuutinen M, Utsch B, Waldegger S.

Hum Genet. 2005 Jul;117(2-3):228-37. Epub 2005 May 14.

PMID:
15895257
22.

Expression of the potassium channel ROMK in adult and fetal human kidney.

Nüsing RM, Pantalone F, Gröne HJ, Seyberth HW, Wegmann M.

Histochem Cell Biol. 2005 Jun;123(6):553-9. Epub 2005 May 14.

PMID:
15895241
23.

Antimicrobial drug use in hospitalised paediatric patients: a cross-national comparison between Germany and Croatia.

Ufer M, Radosević N, Vogt A, Palcevski G, Francetić I, Reinalter SC, Seyberth HW, Vlahović-Palcevski V.

Pharmacoepidemiol Drug Saf. 2005 Oct;14(10):735-9.

PMID:
15880392
24.

Salt handling in the distal nephron: lessons learned from inherited human disorders.

Jeck N, Schlingmann KP, Reinalter SC, Kömhoff M, Peters M, Waldegger S, Seyberth HW.

Am J Physiol Regul Integr Comp Physiol. 2005 Apr;288(4):R782-95. Review.

25.

[Differential diagnosis of a polyhydramnion in hyperprostaglandin E syndrome: a case report].

Marek S, Tekesin I, Hellmeyer L, Kömhoff M, Seyberth HW, Maier RF, Schmidt S.

Z Geburtshilfe Neonatol. 2004 Dec;208(6):232-5. German.

PMID:
15647987
26.

Regulation of CLC-Ka/barttin by the ubiquitin ligase Nedd4-2 and the serum- and glucocorticoid-dependent kinases.

Embark HM, Böhmer C, Palmada M, Rajamanickam J, Wyatt AW, Wallisch S, Capasso G, Waldegger P, Seyberth HW, Waldegger S, Lang F.

Kidney Int. 2004 Nov;66(5):1918-25.

27.
28.

Pharmacotyping of hypokalaemic salt-losing tubular disorders.

Reinalter SC, Jeck N, Peters M, Seyberth HW.

Acta Physiol Scand. 2004 Aug;181(4):513-21. Review.

PMID:
15283765
29.

Osteoarthritis of the knee--clinical assessments and inflammatory markers.

Brenner SS, Klotz U, Alscher DM, Mais A, Lauer G, Schweer H, Seyberth HW, Fritz P, Bierbach U.

Osteoarthritis Cartilage. 2004 Jun;12(6):469-75.

30.
31.

Salt wasting and deafness resulting from mutations in two chloride channels.

Schlingmann KP, Konrad M, Jeck N, Waldegger P, Reinalter SC, Holder M, Seyberth HW, Waldegger S.

N Engl J Med. 2004 Mar 25;350(13):1314-9. No abstract available.

32.

Disruption of TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with secondary hypocalcemia.

Chubanov V, Waldegger S, Mederos y Schnitzler M, Vitzthum H, Sassen MC, Seyberth HW, Konrad M, Gudermann T.

Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2894-9. Epub 2004 Feb 19.

33.

A new mutation (intron 9 +1 G>T) in the SLC12A3 gene is linked to Gitelman syndrome in Gypsies.

Coto E, Rodriguez J, Jeck N, Alvarez V, Stone R, Loris C, Rodriguez LM, Fischbach M, Seyberth HW, Santos F.

Kidney Int. 2004 Jan;65(1):25-9.

34.

Genetics of hereditary disorders of magnesium homeostasis.

Schlingmann KP, Konrad M, Seyberth HW.

Pediatr Nephrol. 2004 Jan;19(1):13-25. Epub 2003 Nov 22. Review.

PMID:
14634861
35.

Induction of microsomal prostaglandin E2 synthase in the macula densa in children with hypokalemic salt-losing tubulopathies.

Kömhoff M, Reinalter SC, Gröne HJ, Seyberth HW.

Pediatr Res. 2004 Feb;55(2):261-6. Epub 2003 Nov 19.

PMID:
14630996
36.
37.

Classification and rescue of ROMK mutations underlying hyperprostaglandin E syndrome/antenatal Bartter syndrome.

Peters M, Ermert S, Jeck N, Derst C, Pechmann U, Weber S, Schlingmann KP, Seyberth HW, Waldegger S, Konrad M.

Kidney Int. 2003 Sep;64(3):923-32.

38.

Low-dose aspirin in pregnancy: maternal and neonatal aspirin concentrations and neonatal prostanoid formation.

Leonhardt A, Bernert S, Watzer B, Schmitz-Ziegler G, Seyberth HW.

Pediatrics. 2003 Jan;111(1):e77-81.

PMID:
12509599
39.
40.

Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects.

Dilger K, Herrlinger C, Peters J, Seyberth HW, Schweer H, Klotz U.

J Clin Pharmacol. 2002 Sep;42(9):985-94.

PMID:
12211224
41.

Barttin increases surface expression and changes current properties of ClC-K channels.

Waldegger S, Jeck N, Barth P, Peters M, Vitzthum H, Wolf K, Kurtz A, Konrad M, Seyberth HW.

Pflugers Arch. 2002 Jun;444(3):411-8. Epub 2002 Apr 9.

PMID:
12111250
42.

Role of cyclooxygenase-2 in hyperprostaglandin E syndrome/antenatal Bartter syndrome.

Reinalter SC, Jeck N, Brochhausen C, Watzer B, Nüsing RM, Seyberth HW, Kömhoff M.

Kidney Int. 2002 Jul;62(1):253-60.

43.

Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family.

Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, Kratz M, Haddad E, Ristoff E, Dinour D, Syrrou M, Nielsen S, Sassen M, Waldegger S, Seyberth HW, Konrad M.

Nat Genet. 2002 Jun;31(2):166-70. Epub 2002 May 28.

PMID:
12032568
44.

Effects of short-term treatment with diclofenac-colestyramine on renal function and urinary prostanoid excretion in patients with type-2 diabetes.

Farker K, Merkel U, Schweer H, Haerting J, Madani SF, Eggers R, Müller UA, Seyberth HW, Hoffmann A.

Eur J Clin Pharmacol. 2002 May;58(2):85-91. Epub 2002 Mar 28.

PMID:
12012138
45.

Heteroligomerization of an Aquaporin-2 mutant with wild-type Aquaporin-2 and their misrouting to late endosomes/lysosomes explains dominant nephrogenic diabetes insipidus.

Marr N, Bichet DG, Lonergan M, Arthus MF, Jeck N, Seyberth HW, Rosenthal W, van Os CH, Oksche A, Deen PM.

Hum Mol Genet. 2002 Apr 1;11(7):779-89.

PMID:
11929850
46.

Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies.

Peters M, Jeck N, Reinalter S, Leonhardt A, Tönshoff B, Klaus G Gü, Konrad M, Seyberth HW.

Am J Med. 2002 Feb 15;112(3):183-90.

PMID:
11893344
47.

Pharmacokinetics of different routes of administration of misoprostol.

Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC.

Hum Reprod. 2002 Feb;17(2):332-6.

PMID:
11821273
48.

Primary gene structure and expression studies of rodent paracellin-1.

Weber S, Schlingmann KP, Peters M, Nejsum LN, Nielsen S, Engel H, Grzeschik KH, Seyberth HW, Gröne HJ, Nüsing R, Konrad M.

J Am Soc Nephrol. 2001 Dec;12(12):2664-72.

49.

Hereditary hypokalemic salt-losing tubulopathies: Bartter-like syndromes.

Peters M, Jeck N, Seyberth HW, Konrad M.

Contrib Nephrol. 2001;(136):157-73. Review. No abstract available.

PMID:
11688378
50.

Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression.

Kammerl MC, Nüsing RM, Seyberth HW, Riegger GA, Kurtz A, Krämer BK.

Pflugers Arch. 2001 Sep;442(6):842-7.

PMID:
11680616

Supplemental Content

Loading ...
Support Center